Arşiv logosu
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
Arşiv logosu
  • Koleksiyonlar
  • Sistem İçeriği
  • Analiz
  • Talep/Soru
  • Türkçe
  • English
  • Giriş
    Yeni kullanıcı mısınız? Kayıt için tıklayın. Şifrenizi mi unuttunuz?
  1. Ana Sayfa
  2. Yazara Göre Listele

Yazar "BALAT, O" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
  • Küçük Resim Yok
    Öğe
    CERVICAL PREGNANCY - CAN AGE AND PARITY BE PREDISPOSING FACTORS
    (Munksgaard Int Publ Ltd, 1994) SONMEZ, AS; KAFKASLI, A; BALAT, O; SARAC, K; URYAN, I; TURHAN, O; AYDIN, NE
    A fifty-year old woman, gravida 17, para 17, presented with profuse vaginal bleeding following curettage in another hospital. At emergency laparotomy total abdominal hysterectomy and bilateral salpingooopherectomy was performed because of intractable hemorrhage. Histopathologic examination revealed endocervical placentation and adenomyosis uteri. The case is presented due to its rarity and possible predisposing factors are discussed.
  • Küçük Resim Yok
    Öğe
    A TRIAL OF LOBAPLATIN (D-19466) IN PLATINUM-RESISTANT OVARIAN-CANCER
    (Academic Press Inc Elsevier Science, 1995) KAVANAGH, JJ; EDWARDS, CL; FREEDMAN, RS; FINNEGAN, MB; BALAT, O; TRESUKOSOL, D; BURK, K
    Long-term survival in epithelial ovarian cancer remains problematic despite multimodality therapy, A fundamental difficulty is the development of tumor resistance to platinum compounds, Analogs have been developed that demonstrate activity in platinum-resistant cell lines both in vitro and in vivo. Lobaplatin (D-19466), a third-generation compound, demonstrates significant activity in carboplatin and cisplatin-resistant cell lines, Lobaplatin was given to 17 assessable patients with platinum-refractory ovarian cancer. The drug was initially administered at a dose of 50 mg/m(2) but was later reduced to 40 mg/m(2) because of excessive thrombocytopenia, Nine patients required red cell transfusions during therapy, Cycles were repeated every 21-35 days (median cycle length 28 days), No objective responses were observed, Lobaplatin has no activity in platinum-resistant epithelial ovarian cancer. (C) 1995 Academic Press, Inc.

| İnönü Üniversitesi | Kütüphane | Rehber | OAI-PMH |

Bu site Creative Commons Alıntı-Gayri Ticari-Türetilemez 4.0 Uluslararası Lisansı ile korunmaktadır.


İnönü Üniversitesi, Battalgazi, Malatya, TÜRKİYE
İçerikte herhangi bir hata görürseniz lütfen bize bildirin

DSpace 7.6.1, Powered by İdeal DSpace

DSpace yazılımı telif hakkı © 2002-2025 LYRASIS

  • Çerez Ayarları
  • Gizlilik Politikası
  • Son Kullanıcı Sözleşmesi
  • Geri Bildirim